Nano-biohybrids combining nanocarriers with cell-penetrating peptides offer a promising strategy to cross the blood-brain barrier and deliver drugs to glioblastoma tumors.
Molecular Trojan horsesCell-penetrating peptide nanocarriers can slip past the blood-brain barrier to deliver drugs directly to glioblastoma tumor cells
What the researchers found
Nano-biohybrids combining nanocarriers with cell-penetrating peptides show promise for crossing the BBB and delivering therapeutics to glioblastoma tumor cells.
Why it matters
Glioblastoma has virtually no effective treatments largely because drugs cannot reach the tumor through the BBB. Cell-penetrating peptide nanocarriers could solve this fundamental delivery problem.
The numbers in context
Reviews CPP types, nanocarrier designs, BBB and BTB penetration mechanisms, and strategies to overcome instability, degradation, and immunogenicity.
How the study worked
Review of nanocarrier-CPP hybrid systems for glioblastoma drug delivery, covering design strategies, BBB penetration mechanisms, and preclinical evidence.
Who was studied
Not applicable (drug delivery review)
What this study cannot tell us
Most evidence is preclinical. CPP-nanocarriers face challenges including rapid systemic clearance, potential off-target accumulation, and manufacturing complexity.
How to read the evidence
Review of preclinical research — summarizes a promising but still early-stage technology. Clinical translation remains years away.
When this study was published
Published in 2025, reviewing the latest advances in CPP-nanocarrier systems for brain tumor drug delivery.
The bigger picture
If CPP-nanocarrier technology can crack the BBB problem, it could transform not just brain cancer treatment but therapy for any neurological condition requiring drug delivery to the brain.
Questions still open
- Which CPP sequences provide the best BBB penetration with minimal off-target effects?
- Can these nanocarriers achieve sufficient drug concentrations in glioblastoma tumors for meaningful clinical benefit?
Common questions
Why is glioblastoma so hard to treat?
How do cell-penetrating peptides help?
Read the original research
Nano-biohybrids with cell-penetrating peptides: A molecular trojans for glioblastoma precision medicine.
International journal of pharmaceutics, 683, 126077
Citation
Phatale, Vivek; Khairnar, Pooja; Shukla, Shalini; Puri, Niharika; Sahane, Prajakta; Srivastava, Saurabh. (2025). Nano-biohybrids with cell-penetrating peptides: A molecular trojans for glioblastoma precision medicine.. International journal of pharmaceutics, 683, 126077. https://doi.org/10.1016/j.ijpharm.2025.126077